Syndax wins U.S. approval for leukemia treatment

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced leukemia.

The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market.

Revuforj was approved to treat adults and children with relapsed or refractory leukemias that have a genetic “rearrangement” called KMT2A. This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high relapse rates and survival of less than a year.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Stuart Orkin receives the third Elaine Redding Brinster Prize for development of sickle cell disease therapy

For his work discovering the basis for hemoglobin gene switching and applying those insights to develop a therapy for sickle cell disease and other blood

September 15, 2023

Lonza’s modest forecast for cell and gene therapies points to uncertainty about sector’s future

As Lonza unveiled its four-year financial predictions on Tuesday, observers were left unsure about the CDMO’s cell and gene therapy (CGT) forecast. Nonetheless, they were

October 20, 2023

Backlash to affirmative action hits pioneering maternal health program for Black women

For Briana Jones, a young Black mother in San Francisco, a city program called the Abundant Birth Project has been a godsend.

November 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.